# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mark Twain (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI013-SYN-TD
- Date: 1905-09-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Winifred Achterberg-Lowe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Thirteen-week review: grief therapy, smoking, a gout flare while away, urate and lipids. **S**

## History of present illness

Mr. Clemens returns eight weeks after his five-week review, after nearly three weeks away in August. Two days after he left, his right big toe became hot, swollen and too painful to walk on; a doctor where he was staying prescribed prednisone 40 mg for five days, and he kept taking allopurinol and colchicine as told. The flare settled within a week. Because he was away, the urate test planned three to four weeks after starting allopurinol was not done until today. He stopped smoking on his quit date at the start of August, smoked two cigars one evening while away, and none since; varenicline causes mild nausea only. His bronchitis from the sick visit has cleared. He has had eleven grief therapy sessions, two of them by telephone while away; he missed one. He sleeps about six hours, writes most mornings and has begun to see friends. No chest tightness. **S**

| Element | Detail |
|---|---|
| Gout | A flare while away, treated with prednisone; allopurinol continued |
| Tobacco | Quit at the start of August; one lapse of two cigars; none for three weeks |
| Grief therapy | Eleven sessions, two by telephone; PG-13-R 32 |
| Chest | No tightness since July |
| Results today | Urate 7.4 mg/dL; LDL 74 mg/dL; ALT 28 U/L; creatinine 1.10 mg/dL |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; weight up |
| Cardiovascular | Negative | No chest tightness |
| Musculoskeletal | Negative | Toe recovered; no muscle aches |
| Psychiatric | Positive | Grief easing; no thoughts of death |

4 systems reviewed. **S**

## Current medications

- Varenicline 1 mg oral tablet, one tablet twice daily with food for twelve weeks, with a quit date in the second week **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Allopurinol 100 mg oral tablet, two tablets daily (200 mg) **S**
- Colchicine 0.6 mg oral tablet, one tablet daily for flare prevention while allopurinol is started, for three to six months **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/78 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 64.9 kg; BMI 21.7 kg/m². All vital signs are synthetic.

Total cholesterol: 156 mg/dL; HDL cholesterol: 46 mg/dL; LDL cholesterol (calculated): 74 mg/dL; Triglycerides: 180 mg/dL (high); ALT: 28 U/L; Uric acid: 7.4 mg/dL (high); Sodium: 139 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 1.1 mg/dL; eGFR (CKD-EPI 1900): 73 mL/min/1.73 m²; Glucose: 98 mg/dL; PHQ-9: 7. All results are synthetic.

## Change since baseline

- Total cholesterol: 228 mg/dL (high) at baseline, 156 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL at baseline, 46 mg/dL at this visit **S**
- LDL cholesterol (calculated): 150 mg/dL (high) at baseline, 74 mg/dL at this visit **S**
- Triglycerides: 170 mg/dL (high) at baseline, 180 mg/dL (high) at this visit **S**
- ALT: 24 U/L at baseline, 28 U/L at this visit **S**
- Uric acid: 8.6 mg/dL (high) at baseline, 7.4 mg/dL (high) at this visit **S**
- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 1.08 mg/dL at baseline, 1.1 mg/dL at this visit **S**
- eGFR (CKD-EPI 1900): 74 mL/min/1.73 m² at baseline, 73 mL/min/1.73 m² at this visit **S**
- Glucose: 101 mg/dL (high) at baseline, 98 mg/dL at this visit **S**
- PHQ-9: 11 at baseline, 7 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 130/78, pulse 72; weight 64.9 kg |
| Respiratory | Clear |
| Musculoskeletal | Right first toe joint normal; no tophi |
| Psychiatric | Engaged and humorous; speaks of his wife with less pain |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Gout on allopurinol** (M10.9). Flares are common in the first months of urate-lowering therapy, even with colchicine. The urate check was delayed by his trip; today it is 7.4 mg/dL, still above the target of 6. eGFR 73. **S**
   - Allopurinol 200 mg daily.
   - Continue colchicine 0.6 mg daily.
   - Urate in four to five weeks.
2. **Nonobstructive coronary artery disease** (I25.10). LDL 74 mg/dL, 51 percent lower than at intake; ALT normal; no muscle aches on atorvastatin with colchicine. No chest tightness. Blood pressure 130/78 mmHg. **S**
   - Continue atorvastatin 40 mg and aspirin 81 mg.
   - Lipids again in six to twelve months.
3. **Tobacco use disorder, early remission** (F17.290). Stopped at the start of August with one lapse; three weeks without a cigar. **S**
   - Continue varenicline 1 mg twice daily to complete twelve weeks; the quitline as needed.
4. **Prolonged grief disorder, improving** (F43.81). PG-13-R 32 and PHQ-9 7 after eleven sessions. Safety reviewed: no thoughts of death. **S**
   - Continue weekly grief therapy.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Grief severity (PG-13-R) and the DSM-5-TR prolonged grief disorder criteria | At diagnosis and every four weeks during therapy | Completed today | PG-13-R 32 |
| Referral | Prolonged grief disorder therapy: sessions attended | Weekly for sixteen weeks | Completed today | Eleven sessions, two by telephone while away; one missed |
| Survey | Depression (PHQ-9), to watch for major depression | At baseline and every four weeks during treatment | Completed today | PHQ-9 7, item 9 scored 0 |
| Survey | Suicide risk review, safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of death; safety plan kept |
| Self-management | Sleep, without sedative-hypnotics | Every visit | Completed today | About six hours |
| Self-management | Social contact and his writing | Every visit | Completed today | Writing most mornings; seeing friends weekly |
| Self-management | Tobacco use (cigars a day), readiness and counseling | Every visit | Completed today | No cigars for three weeks after one lapse |
| Medication safety | Varenicline: adherence, nausea, sleep and mood changes | Every visit | Completed today | Mild nausea only; no change in mood or sleep from varenicline |
| Examination | Chest symptoms on exertion | Every visit | Completed today | None since July |
| Examination | Blood pressure | Every visit | Completed today | 130/78 mmHg |
| Laboratory | Lipid panel and ALT on a statin | 4 to 12 weeks after starting, then every 3 to 12 months | Completed today | Eight weeks on atorvastatin: total cholesterol 156, HDL 46, LDL 74 (51 percent lower), triglycerides 180 mg/dL; ALT 28 U/L |
| Medication safety | Aspirin and statin adherence, bleeding and muscle symptoms | Every visit | Completed today | Taking both daily; no bleeding or muscle aches |
| Laboratory | Serum urate during allopurinol titration | Every 2 to 5 weeks while titrating, then every 6 months | Deferred | The check due three to four weeks after starting allopurinol was missed while he was away, which delayed the first dose increase by about four weeks; a flare occurred in that time, but flares are common early in treatment and he had no lasting harm. Today 7.4 mg/dL. Corrective action: urate four to five weeks after each change at a laboratory near wherever he is staying |
| Self-management | Gout flares and colchicine prophylaxis | Every visit | Completed today | One flare in August treated with prednisone while away; allopurinol and colchicine continued |
| Laboratory | Kidney function on allopurinol and colchicine | With each urate check | Completed today | Sodium 139, potassium 4.5 mmol/L, creatinine 1.10 mg/dL, eGFR 73, glucose 98 mg/dL |

## Goal progress

- PG-13-R below 30 and back to writing and seeing friends. In progress; target 1905-10-16. **S**
- No thoughts of death and a safety plan he would use. Outcome by 1905-09-11: Passive thoughts of death at intake; none since the five-week visit; safety plan kept. **S**
- Stop smoking cigars. In progress; target 1905-10-16. **S**
- LDL cholesterol at least 50 percent lower on a high-intensity statin. Outcome by 1905-09-11: LDL 150 to 74 mg/dL (51 percent lower) at eight weeks. **S**
- Serum urate below 6 mg/dL and no gout flares. In progress; target 1905-10-16. **S**
- Six or more hours of sleep on most nights without a sleeping pill. In progress; target 1905-10-16. **S**

## Medication changes

- Stopped: Allopurinol 100 mg oral tablet, one tablet daily **S**
- Started: Allopurinol 100 mg oral tablet, two tablets daily (200 mg) **S**

## Guideline basis

- Prolonged Grief Disorder (DSM-5-TR criteria, patient and family information) (2022), American Psychiatric Association
- Validation of the new DSM-5-TR criteria for prolonged grief disorder and the PG-13-Revised (PG-13-R) scale (2021), World Psychiatry 2021;20(1):96-106 (Prigerson HG et al.)
- Treatment of complicated grief: a randomized controlled trial (2005), JAMA 2005;293(21):2601-8 (Shear K et al.)
- Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016), JAMA Psychiatry 2016;73(7):685-94 (Shear MK et al.)
- Loss of partner and suicide risks among oldest old: a population-based register study (2004), Age and Ageing 2004;33(4):378-83 (Erlangsen A et al.)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain (2021), American Heart Association and American College of Cardiology (Circulation 2021;144(22):e368-e454)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2020 American College of Rheumatology Guideline for the Management of Gout (2020), American College of Rheumatology (Arthritis Care & Research 2020;72(6):744-760)
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease, hyperlipidemia, and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Annual wellness visit in two weeks. Eighteen-week review in five weeks with a urate test. Call the clinic or 988 at any time. **S**
- Next scheduled visit 1905-09-25: subsequent annual wellness visit. **S**
